Pathology is a necessary and informative tool in oncology clinical trials

Journal of Pathology

Volumn 232, Issue 2, 2014, Pages 185-189

  Nagtegaal, Iris D ^a   West, Nicholas P ^b   Van Krieken, J Han J M ^a   Quirke, Phil ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

clinical trials; end point; oncology; quality assurance; response; staging; stratification

Indexed keywords

BIOLOGICAL MARKER;

CANCER STAGING; CANCER THERAPY; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; HISTOPATHOLOGY; HUMAN; ONCOLOGY; PATHOLOGIST; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; TREATMENT RESPONSE;

CLINICAL TRIALS; END POINT; ONCOLOGY; QUALITY ASSURANCE; RESPONSE; STAGING; STRATIFICATION;

CLINICAL TRIALS AS TOPIC; ENDPOINT DETERMINATION; HUMANS; MEDICAL ONCOLOGY; NEOPLASM STAGING; NEOPLASMS; PATHOLOGY, CLINICAL; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; QUALITY INDICATORS, HEALTH CARE; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 84890290279     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4261     Document Type: Review

References (31)

1. Quirke P, Cuvelier C, Ensari A, et al., Evidence-based medicine: the time has come to set standards for staging. J Pathol 2010; 221: 357-360.
2. Quirke P, Williams GT, Ectors N, et al., The future of the TNM staging system in colorectal cancer: time for a debate? Lancet Oncol 2007; 8: 651-657.
3. Nagtegaal ID, Quirke P, Schmoll HJ,. Has the new TNM classification for colorectal cancer improved care? Nat Rev Clin Oncol 2012; 9: 119-123.
4. Mekenkamp LJ, Heesterbeek KJ, Koopman M, et al., Mucinous adenocarcinomas: poor prognosis in metastatic colorectal cancer. Eur J Cancer 2012; 48: 501-509.
5. Tol J, Nagtegaal ID, Punt CJ,. BRAF mutation in metastatic colorectal cancer. N Engl J Med 2009; 361: 98-99.
6. Richman SD, Seymour MT, Chambers P, et al., KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 2009; 27: 5931-5937.
7. Seymour MT, Brown SR, Middleton G, et al., Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO) a prospectively stratified randomised trial. Lancet Oncol 2013; 14: 749-759.
8. Quirke P, Steele R, Monson J, et al., Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial. Lancet 2009; 373: 821-828.
9. Sebag-Montefiore D, Stephens RJ, Steele R, et al., Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016) a multicentre, randomised trial. Lancet 2009; 373: 811-820.
10. van Gijn W, Marijnen CA, Nagtegaal ID, et al., Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 2011; 12: 575-582.
11. Nagtegaal ID, Quirke P,. What is the role for the circumferential margin in the modern treatment of rectal cancer? J Clin Oncol 2008; 26: 303-312.
12. Group MS,. Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study. B Med J 2006; 333: 779.
13. Nagtegaal ID, Kranenbarg EK, Hermans J, et al., Pathology data in the central databases of multicenter randomized trials need to be based on pathology reports and controlled by trained quality managers. J Clin Oncol 2000; 18: 1771-1779.
14. Gray RG, Quirke P, Handley K, et al., Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J Clin Oncol 2011; 29: 4611-4619.
15. Guillou PJ, Quirke P, Thorpe H, et al., Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial. Lancet 2005; 365: 1718-1726.
16. FOxTROT Collaborative Group. Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial. Lancet Oncol 2012; 13: 1152-1160.
17. van Krieken JH, Jung A, Kirchner T, et al., KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch 2008; 453: 417-431.
18. van Krieken JH, Normanno N, Blackhall F, et al., Guideline on the requirements of external quality assessment programs in molecular pathology. Virchows Arch 2013; 462: 27-37.
19. Collinson FJ, Jayne DG, Pigazzi A, et al., An international, multicentre, prospective, randomised, controlled, unblinded, parallel-group trial of robotic-assisted versus standard laparoscopic surgery for the curative treatment of rectal cancer. Int J Colorect Dis 2012; 27: 233-241.
20. Kennedy RH, Francis A, Dutton S, et al., EnROL a multicentre randomised trial of conventional versus laparoscopic surgery for colorectal cancer within an enhanced recovery programme. Br Med J Cancer 2012; 12: 181.
21. West NP, Grabsch H, Treanor D, et al., Quantitative assessment of tumor cell density in rectal cancer following three different preoperative therapies compared to surgery alone. J Clin Oncol 2010; 28: 3651.
22. Gosens MJ, Klaassen RA, Tan-Go I, et al., Circumferential margin involvement is the crucial prognostic factor after multimodality treatment in patients with locally advanced rectal carcinoma. Clin Cancer Res 2007; 13: 6617-6623.
23. Rullier A, Laurent C, Capdepont M, et al., Impact of tumor response on survival after radiochemotherapy in locally advanced rectal carcinoma. Am J Surg Pathol 2010; 34: 562-568.
24. Capirci C, Valentini V, Cionini L, et al., Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients. Int J Radiat Oncol Biol Phys 2008; 72: 99-107.
25. Maas M, Nelemans PJ, Valentini V, et al., Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer a pooled analysis of individual patient data. Lancet Oncol 2010; 11: 835-844.
26. Martin ST, Heneghan HM, Winter DC,. Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer. Br J Surg 2012; 99: 918-928.
27. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM305501.pdf [accessed 31 August 2013].
28. Mandard AM, Dalibard F, Mandard JC, et al., Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 1994; 73: 2680-2686.
29. Vironen J, Juhola M, Kairaluoma M, et al., Tumour regression grading in the evaluation of tumour response after different preoperative radiotherapy treatments for rectal carcinoma. Int J Colorect Dis 2005; 20: 440-445.
30. Dworak O, Keilholz L, Hoffmann A,. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorect Dis 1997; 12: 19-23.
31. Folkesson J, Birgisson H, Pahlman L, et al., Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol 2005; 23: 5644-5650.